Performance of CFC free propellant- driven MDI of fluticasone propionate

Abstract

866-871Metered dose inhalers (MDIs) of fluticasone propionate were developed for treatment of asthma and chronic ob­structive pulmonary disease. MDIs with hydrofluoroalkanes based propellants were formulated with various doses, overages and various concentrations of alcohol. Optimum requirements were found as follows: effective valve delivery, overdoses (15%); 100% drug delivery, overages (20%); and emitted dose and fine particle fraction, alcohol content (5-10%)